• 39: The Medicine Box: Cipla’s Umang Vohra on COVID-19 portfolio, upcoming drugs, US business outlook and more

  • Apr 2 2022
  • Duración: 21 m
  • Podcast

39: The Medicine Box: Cipla’s Umang Vohra on COVID-19 portfolio, upcoming drugs, US business outlook and more Por arte de portada

39: The Medicine Box: Cipla’s Umang Vohra on COVID-19 portfolio, upcoming drugs, US business outlook and more

Escúchala gratis

Ver detalles del espectáculo

  • Resumen

  • Pharma industry’s Robinhood, Cipla is looking to increase its presence in the US market, the company’s MD and Global CEO Umang Vohra.

    In this edition of The Medicine Box Podcast, CNBC-TV18’s Ekta Batra talks to Vohra about Cipla’s plan to capture a larger share of the US market, the firm’s COVID-19 portfolio – from Tocilizumab to Remdesivir to Favipiravir, new products, growth outlook and more.

    Cipla, which is India’s third largest pharma company and is present in more than 80 countries with over 46 manufacturing facilities, is looking to manufacture complex drugs and injectables in respiratory and cancer segments, Vohra said.

    Tune in to The Medicine Box Podcast for more 
    Más Menos
activate_primeday_promo_in_buybox_DT
Más Menos

Lo que los oyentes dicen sobre 39: The Medicine Box: Cipla’s Umang Vohra on COVID-19 portfolio, upcoming drugs, US business outlook and more

Calificaciones medias de los clientes

Reseñas - Selecciona las pestañas a continuación para cambiar el origen de las reseñas.

Reseñas de Audible.com

Opiniones de Amazon
No hay comentarios disponibles